STOK
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Stoke Therapeutics completed enrollment in the Phase 3 EMPEROR study of zorevunersen for Dravet syndromeJul 1, 2026
- Stoke Therapeutics dosed the first patient in a Phase 1 study of STK-002 for autosomal dominant optic atrophyFeb 11, 2026
- Stoke Therapeutics and Biogen announce presentations of clinical data from Zorevunersen studies for potential treatment of Dravet Syndrome at 36th International Epilepsy CongressAug 25, 2025
- Stoke Therapeutics and Biogen announce first patient dosed in Phase 3 EMPEROR study of Zorevunersen, a potential disease-modifying treatment for Dravet SyndromeAug 11, 2025